
Yet another investigational drug appears to have faltered on the rocky path to develop anti-obesity treatments. Takeda Pharmaceutical Company and …
Abbott has pulled its anti-obesity drug Meridia in the US after recent trials showed it increased the risk of stroke …

Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

